ArticleMolecular and clinical oncology2017
There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival.
Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.Disease markers · 2020Trial
- Integrated Assessment of HIF-1α and SOD2 Expression and Their Prognostic Implications in Triple-Negative Breast Cancer.International journal of molecular sciences · 2026Article
- Superoxide Dismutase (rs2070424, rs4880, rs2536512) and Catalase (rs794316, rs1001179) SNPs and their Association with Breast Cancer Risk: Findings from a Hospital Based Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Val16A SOD2 Polymorphism Promotes Epithelial-Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells.Antioxidants (Basel, Switzerland) · 2021Article
- Gene expression in triple-negative breast cancer in relation to survival.Breast cancer research and treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common diagnosed cancer among females worldwide. Superoxide dismutase 2 (SOD2), an antioxidant enzyme, may break the balance between the oxidant and antioxidant system to induce various diseases. The present study aimed to clarify the association between the SOD2 Val-16Ala polymorphism and breast cancer risk or survival. Thus, a meta-analysis of the relevant articles retrieved from PubMed and EMBASE databases was conducted to illuminate the association with odd ratios (ORs) or hazards ratios (HRs). A total of 26 eligible publications (n=38,008) were available in risk analysis and eight publications (n=5,746) in survival analysis. The results demonstrated a marginal association between breast cancer risk and SOD2 polymorphism in Caucasian patients [TT vs. CT + CC: (OR, 0.94; 95% confidence interval (CI), 0.88-1.00)]. However, no other positive results were observed in risk and survival of breast cancer in the whole study [T vs. C: (OR, 0.99; 95% CI, 0.96-1.02); CT vs. CC: (OR, 1.00; 95% CI, 0.95-1.05); TT vs. CC: (OR, 0.98; 95% CI, 0.92-1.05); TT vs. CT + CC: (OR, 1.00; 95% CI, 0.95-1.05); CT + TT vs. CC: (OR, 0.99; 95% CI, 0.95-1.05)]. The present meta-analysis indicated that there was no significant relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival, although in Caucasian patients, the SOD2 TT genotype may marginally decrease the risk of breast cancer in comparison to the CT + CC genotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.